depolarising muscle relaxants.

centrally-acting muscle relaxants.

spasmolytics.

non-depolarising muscle relaxants.

include tubocurarine.

act at muscarinic cholinergic receptors.

prevents acetylcholine from binding to cholinoceptors.

does not cause depolarisation at the motor endplate.

are G-protein-coupled receptors.

are ligand-gated ion channels.

stimulate Ca2+ release upon activation.

allows passage of Na+ upon activation.

is a structural analogue to ACh.

is a non-competitive antagonist at the nicotinic receptor.

binding to the receptor is surmountable.

prevent the passage of Ca2+ thru the channel when it binds.

is extracted from curare poison.

causes initial fasciculations of muscles.

use leads to flaccid paralysis.

binding causes Ca2+ release.

can only be administered parenterally.

is metabolised by plasma cholinesterases.

does not pass into the brain.

is used as part of general anaesthesia.

is structurally similar to ACh.

binding opens the ligand-gated Na+ channel.

binding to nicotinic receptor is not surmountable.

is removed/ metabolised slower than ACh by acetylcholin-esterases.

is similar to 2 ACh molecules bound together.

causes MEP depolarisation.

causes Ca2+ releases from the sarcoplasmic reticulum.

inhibit further activation of the nicotinic receptor.

can cause extreme muscle stiffness and elevated body temperature.

is orally active.

is used to facilitate intubation.

crosses the blood-brain barrier.

Neostigmine -- increased efficacy

General anaesthetics -- synergisticic block of nicotinic receptor.

Aminoglycoside antibiotics -- reduced efficacy.

Aminoglycoside antibiotics -- inhibit ACh release from presynaptic neurons.

increase competition for drug binding at nicotinic receptors.

increase tubocurarine's efficacy.

reduce succinylcholine's duration of action.

enhance muscular contraction.

occurs when tubocurarine is combined with inhaled anaesthesia.

is characterised by extreme muscle stiffness and low blood pH.

happens when there is excessive Ca2+ release from sarcoplasmic reticulum.

is treated by succinylcholine.

is a muscle relaxant.

activates Ryanodine receptors on sarcoplasmic reticulum.

can treat malignant hyperthermia.

inhibits sarcoplasmic Ca2+ release.

Baclofen -- GABA-A allosteric modifier

Diazepam -- GABA-B agonist

Cyclobenzaprine -- serotonin 5HT-2 receptor antagonist